Award
National Institute on Aging 5R01AG075122-05
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Recipient
University of Arizona, Tucson, AZ
Award Amount
$1,353,297.00
Ceiling
$1,353,297.00
Awarded
May 25, 2026
Identifier
5R01AG075122-05
This award funds a Phase 2 clinical trial to evaluate PhytoSERM's efficacy and safety in preventing menopause-associated decline in brain metabolism and cognition in women, addressing Alzheimer's disease risk and menopausal symptoms.
Description
Phase 2 clinical development of PhytoSERM, a selective estrogen receptor beta modulator, to assess safety and efficacy in peri- and postmenopausal women focusing on brain glucose metabolism, cognitive function, vasomotor symptoms, sleep, mood, and MRI biomarkers.